{"id":597655,"date":"2025-11-27T18:36:32","date_gmt":"2025-11-27T18:36:32","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/597655\/"},"modified":"2025-11-27T18:36:32","modified_gmt":"2025-11-27T18:36:32","slug":"aurobindo-pharma-sees-europe-as-a-growth-engine","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/597655\/","title":{"rendered":"Aurobindo Pharma sees Europe as a growth engine"},"content":{"rendered":"<p>Aurobindo Pharma&#8217;s growth story spans Europe, the US, and multiple verticals.<\/p>\n<p>In Europe, the Indian generics manufacturer has a presence in the UK and nine EU markets, and it is one of the high-growth regions.<\/p>\n<p>Aurobindo&#8217;s Europe business CEO Venugopalan Muralidharan told the Indian television channel ET Now that the company has steadily increased its portfolio breadth.<\/p>\n<p>The teams understand the diverse European market archetypes, and they are &#8216;very much tuned&#8217; to the markets they are operating in, he added.<\/p>\n<p>Muralidharan said Aurobindo started as a plain vanilla generics drug manufacturer, but it now offers a wider range of products, including biosimilars, injectables, and inhalers.<\/p>\n<p>The portfolio is supported by in-house development and in-licensing.<\/p>\n<p>As for biosimilars, Aurobindo recently got three approvals through the European Medicines Agency and one approval through the UK MHRA.<\/p>\n<p>In the UK, <a data-linked-post=\"2673903362\" href=\"https:\/\/www.pharmacy.biz\/aurobindo-pharma-zentiva-deal\/\" target=\"_blank\" rel=\"noopener\">Aurobindo Pharma&#8217;s<\/a> subsidiary CuraTeQ Biologics got marketing authorisation for Dazublys, its biosimilar version of trastuzumab.<\/p>\n<p>It is used to treat certain types of breast and stomach cancers.<\/p>\n<p>Muralidharan said that while operating in the European markets, pricing pressure, currency volatility, and dealing with multiple regulators are the major challenges.<\/p>\n<p>He pointed out that out of the nine markets in Europe, where Aurobindo operates, it is among the top 10 in eight countries.<\/p>\n<p>Apart from the UK, the company operates in France, Germany, Spain, Portugal, Italy, Netherlands, Belgium, Poland and Malta.<\/p>\n<p>The company&#8217;s CFO, Subramaniam Santhanam, told the news channel that it has paused investments in greenfield and brownfield projects, as they have long gestation periods.<\/p>\n<p>Aurobindo is ramping up its existing investment to add shareholder value, he added.<\/p>\n<p>The company has more than 30 plants, and it is trying to increase its capacities.<\/p>\n","protected":false},"excerpt":{"rendered":"Aurobindo Pharma&#8217;s growth story spans Europe, the US, and multiple verticals. In Europe, the Indian generics manufacturer has&hellip;\n","protected":false},"author":2,"featured_media":597656,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[187791,187790,2000,299,5187,60539,19213],"class_list":{"0":"post-597655","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-aurobindo-pharma","9":"tag-ema","10":"tag-eu","11":"tag-europe","12":"tag-european","13":"tag-generic-medicines","14":"tag-mhra"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115623112460903252","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/597655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=597655"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/597655\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/597656"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=597655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=597655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=597655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}